NASDAQ · STOCK
Elevance Health
$375.86
52W $273.71 – $436.24
54/100
$81.51B
16.7
0.68
Is ELV Bullish or Bearish?
Mixed.
Innellis AI committee rates Elevance Health (ELV) Watch with a composite score of 54/100
, based on 7 analysts with 86% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.48 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.52 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — news sentiment is positive (+0.40 across 37 articles, 14d) — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.40 across 37 articles, 14d) — News
Bear Case
- EPS declining -4.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Current ratio of 0.19 is tight -- limited short-term liquidity cushion — Risk
- Bollinger bandwidth of 20.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
54/100
Agreement
86%
Analysts
7
Conviction
High
Sector Rank
Top 64%
of 93 Healthcare peers
Value Analyst
neutral
58
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -4.2% YoY despite any revenue growth
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
47
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Current ratio of 0.19 is tight -- limited short-term liquidity cushion
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 37 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 52.6 to 53.5.
- Conviction strengthened -- analysts aligned more closely.
- Committee agreement increased sharply from 57% to 86%.
- New bearish signals: 3 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst, Risk Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Risk Analyst: stance bearish->neutral; score 35->47 (+12); +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
38.5
Neutral
MACD Histogram
-2.199
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$368.40
Resistance
$382.58
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$381.12
Below
EMA 21
$388.27
Below
EMA 50
$387.58
Below
EMA 200
$364.28
Above
Fundamental Analysis
Valuation
96
Growth
59
Profitability
0
Financial Health
75
Cash Flow
37
Valuation
P/E Ratio
16.7×
P/B Ratio
1.82×
PEG Ratio
-3.71
Dividend Yield
0.02%
52W High
$436.24
52W Low
$273.71
Quality & Growth
ROE
12.9%
ROA
4.7%
Gross Margin
39.0%
Operating Margin
3.5%
Revenue Growth YoY
—
Debt / Equity
0.69
AI Fundamental Assessment
P/E ratio of 16.7 (inexpensive relative to a 15-40x range); Price-to-book of 1.8x; PEG ratio of -3.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.0%; Gross margin of 0.4%; Current ratio of 1.52 (tight short-term liquidity); Debt-to-equity of 0.69; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (28.86); Most recent quarter beat estimates by 18.9%; 4 consecutive earnings beats; EPS growth decelerating (+277.8% -> -40.8% QoQ); Average YoY EPS growth of -15.7%; Analyst estimates rising over recent quarters
Get the Full ELV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →